RB1 and cancer: Indeed, two erlotinib-resistant cell lines (MGH125 and MGH141), a resistant patient sample (Patient #10) and two out of four pre-treatment adenocarcinoma samples from patients whose cancers transformed to SCLC (Patients #2 and #6), were also negative for RB.